End of contract for Drug and Therapeutics Bulletin: ChoicesBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7552.1273-b (Published 25 May 2006) Cite this as: BMJ 2006;332:1273
- Piero Baglioni, consultant physician ()
EDITOR—In the February 2005 issue of the Drug and Therapeutics Bulletin I learnt that the cost of oxycodone is four times the cost of regular long acting morphine, without any special advantage in terms of efficacy or tolerability. I adjusted my practice accordingly. The bulletin's opinion has been confirmed in a recent meta-analysis from the Marsden Hospital in London and Bristol University.1
I could quote many other examples like this, which leads me to ask: if saving money is the issue, why kill one of the few practical and respected sources of rational prescribing?2 The logic supporting this choice seems to me as puzzling as extending pub hours to reduce antisocial drinking.
Competing interests None declared.